TWi Pharmaceuticals announced it has received final approval from the Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for its Donepezil HCl Tablets, the generic version of Eisai’s Aricept.
Aricept is a reversible acetylcholinesterase inhibitor indicated for the treatment of Alzheimer’s dementia. It is thought to exert its therapeutic effect by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase.
Donepezil HCl Tablets will be available in a 23mg strength in the near future.
For more information visit TWiPharma.com.